The in silico identification of potent anti-cancer agents by targeting the ATP binding site of the N-domain of HSP90

References

• J.L. Johnson, Evolution and function of diverse HSP90 homologs and cochaperone proteins, BBA-Mol. Cell Res. 1823 (2012), pp. 607–613.
   Web of Science ®Google Scholar
• S.S. Roy and M. Kapoor, In silico identification and computational analysis of the nucleotide binding site in the c-terminal domain of HSP90, J. Mol. Graph. Model. 70 (2016), pp. 253–274.
   PubMed Web of Science ®Google Scholar
• J. Li, J. Soroka, and J. Buchner, The HSP90 chaperone machinery: Conformational dynamics and regulation by co-chaperones, BBA-Mol. Cell Res. 1823 (2012), pp. 624–635.
   Web of Science ®Google Scholar
• S. Messaoudi, J.F. Peyrat, J.D. Brion, and M. Alami, Recent advances in HSP90 inhibitors as antitumor agents, Anticancer Agents Med. Chem. 8 (2008), pp. 761–782.
   Web of Science ®Google Scholar
• İ. Koca, M. Gümüş, A. Özgür, A. Dişli, and Y. Tutar, A novel approach to inhibit heat shock response as anticancer strategy by coumarine compounds containing thiazole skeleton, Anticancer Agents Med. Chem. 15 (2015), pp. 916–930.
   Web of Science ®Google Scholar
• J.H. Jeong, Y.J. Oh, Y. Lho, S.Y. Park, K.H. Liu, E. Ha, and Y.H. Seo, Targeting the entry region of HSP90’s ATP binding pocket with a novel 6,7- dihydrothieno[3,2-c]pyridin-5(4H)-yl amide, Eur. J. Med. Chem. 124 (2016), pp. 1069–1080.
   Web of Science ®Google Scholar
• C. Zhang, X. Wang, H. Liu, M. Zhang, M. Geng, L. Sun, A. Shen, and A. Zhang, Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (HSP90) inhibitors, Eur. J. Med. Chem. 125 (2017), pp. 315–326.
   Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, Towards the in-silico design of new HSP90 inhibitors: Molecular docking and 3D-QSAR CoMFA studies of tetrahydropyrido [4, 3-d] pyrimidine derivatives as HSP90 inhibitors, Med. Chem. 14 (2018), Doi: 10.2174/1573406414666180321151029.
   Google Scholar
• Y. Li, T. Zhang, S.J. Schwartz, and D. Sun, New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential, Drug Resist. Updates 12 (2009), pp. 17–27.
   Google Scholar
• J.R. Sydor, E. Normant, C.S. Pien, J.R. Porter, J. Ge, L. Grenier, R.H. Pak, J.A. Ali, M.S. Dembski, J. Hudak, J. Patterson, C. Penders, M. Pink, M.A. Read, J. Sang, C. Woodward, Y. Zhang, D.S. Grayzel, J. Wright, J.A. Barrett, V.J. Palombella, J. Adams, and J.K. Tong, Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90, Proc. Natl. Acad. Sci. USA 103 (2010), pp. 17408–17413.
   Web of Science ®Google Scholar
• K. Sidera and E. Patsavoudi, HSP90 inhibitors: Current development and potential in cancer therapy, Recent Pat. Anticancer Drug Discov. 9 (2014), pp. 1–20.
   PubMed Web of Science ®Google Scholar
• L.M. Butler, R. Ferraldeschi, H.K. Armstrong, M.M. Centenera, and P. Workman, Maximizing the therapeutic potential of HSP90 inhibitors, Mol. Cancer Res. 13 (2015), pp. 1445–1451.
   PubMed Web of Science ®Google Scholar
• A. Dhawan, D. Nichol, F. Kinose, M.E. Abazeed, A. Marusyk, E.B. Haura, and J.G. Scott, Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer, Sci. Rep. 7 (2017), pp. 1232.
   Google Scholar
• A.C. Lai and C.M. Crews, Induced protein degradation: An emerging drug discovery paradigm, Nat. Rev. Drug Discov. 16 (2017), pp. 101–114.
   PubMed Web of Science ®Google Scholar
• A.K. Saxena, S. Saxena, and S.S. Chaudhaery, Molecular modelling and docking studies on heat shock protein 90 (HSP90) inhibitors, SAR QSAR Environ. Res. 21 (2010), pp. 1–20.
   Google Scholar
• S. Saxena, S.S. Chaudhaery, K. Varshney, and A.K. Saxena, Pharmacophore-based virtual screening and docking studies on HSP90 inhibitors, SAR QSAR Environ. Res. 21 (2010), pp. 445–462.
   Google Scholar
• R. Sanam, S. Tajne, R. Gundla, S. Vadivelan, P.K. Machiraju, R. Dayam, L. Narasu, S. Jagarlapudi, and N. Neamati, Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors, J. Mol. Graph. Model. 28 (2010), pp. 472–477.
   PubMed Web of Science ®Google Scholar
• N.R. Dunna, S. Bandaru, U.R. Akare, S. Rajadhyax, V.R. Gutlapalli, M. Yadav, and A. Nayarisseri, Multiclass comparative virtual screening to identify novel HSP90 inhibitors: A therapeutic breast cancer drug target, Curr. Top. Med. Chem. 15 (2015), pp. 57–64.
   PubMed Web of Science ®Google Scholar
• S. Sakkiah, S. Thangapandian, S. John, and K.W. Lee, Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors, Eur. J. Med. Chem. 46 (2011), pp. 2937–2947.
   Web of Science ®Google Scholar
• S. Sakkiah, S. Thangapandian, S. John, Y.J. Kwon, and K.W. Lee, 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors, Eur. J. Med. Chem. 45 (2010), pp. 2132–2140.
   Web of Science ®Google Scholar
• R. Huang, D.M. Ayine-Tora, M. Nasri Muhammad Rosdi, Y. Li, J. Reynisson, and I.K.H. Leung, Virtual screening and biophysical studies lead to HSP90 inhibitors, Bioorg. Med. Chem. Lett. 27 (2017), pp. 277–281.
   PubMed Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, The identification of new ATAD2 bromodomain inhibitors: The application of combined ligand and structure-based virtual screening, SAR QSAR Environ. Res. 28 (2017), pp. 957–971.
   Google Scholar
• B. Sepehri and R. Ghavami, The identification of new CD38 inhibitors by combined structure and ligand based virtual screening approaches of ZINC database, Lett. Drug Des. Discov. 15 (2018), pp. 654–660.
   Google Scholar
• istar; software available at http://istar.cse.cuhk.edu.hk/idock/.
   Google Scholar
• H. Li, K.S. Leung, P.J. Ballester, and M.H. Wong, iStar: A web platform for large-scale protein-ligand docking, PLOS ONE 9 (2014), pp. e85678.
   PubMed Web of Science ®Google Scholar
• J.J. Irwin and B.K. Shoichet, ZINC – A free database of commercially available compounds for virtual screening, J. Chem. Inf. Model. 45 (2005), pp. 177–182.
   PubMed Web of Science ®Google Scholar
• H. Li, K.S. Leung, and M.H. Wong, iDock: A multithreaded virtual screening tool for flexible ligand docking, Proceedings of the 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), San Diego, 9–12 May 2012, pp. 77–84.
   Google Scholar
• ZINC; software available at http://zinc.docking.org.
   Google Scholar
• J.J. Irwin, T. Sterling, M.M. Mysinger, E.S. Bolstad, and R.G. Coleman, ZINC: A free tool to discover chemistry for biology, J. Chem. Inf. Model. 52 (2012), pp. 1757–1768.
   PubMed Web of Science ®Google Scholar
• AutoDock Vina; software available at http://vina.scripps.edu/.
   Google Scholar
• O. Trott and A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, J. Comput. Chem. 31 (2010), pp. 455–461.
   Google Scholar
• MGLTools 1.5.6, Molecular Graphics Laboratory (MGL) of The Scripps Research Institute. Software available at http://mgltools.scripps.edu.
   Google Scholar
• Discovery Studio 16.1.0; software available at www.accelrys.com.
   Google Scholar
• A. Lauria, M. Ippolito, and A.M. Almerico, Inside the HSP90 inhibitors binding mode through induced fit docking, J. Mol. Graph. Model. 27 (2009), pp.712–722.
   PubMed Web of Science ®Google Scholar
• P. Banerjee, A.O. Eckert, A.K. Schrey, and R. Preissner, ProTox-II: A webserver for the prediction of toxicity of chemicals, Nucleic Acids Res. 46 (2018), pp. W257–W263.
   Google Scholar
• ProTox-II; software available at http://tox.charite.de/protox_II/index.php?site=compound_input/.
   Google Scholar
• A.J. Woodhead, H. Angove, M.G. Carr, G. Chessari, M. Congreve, J.E. Coyle, J. Cosme, B. Graham, P.J. Day, R. Downham, L. Fazal, R. Feltell, E. Figueroa, M. Frederickson, J. Lewis, R. McMenamin, C.W. Murray, M.A. O’Brien, L. Parra, S. Patel, T. Phillips, D.C. Rees, S. Rich, D.M. Smith, G. Trewartha, M. Vinkovic, B. Williams, and A.J.A. Woolford, Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3- dihydroisoindol-2-yl] methanone (AT13387), a novel inhibitor of the molecular chaperone HSP90 by fragment based drug design, J. Med. Chem. 53 (2010), pp. 5956–5969.
   Web of Science ®Google Scholar
• C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliver. Rev. 46 (2001), pp. 3–26.
   PubMed Web of Science ®Google Scholar